Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “overweight” rating reissued by research analysts at Barclays PLC in a research report issued to clients and investors on Thursday. They presently have a $105.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $80.00. Barclays PLC’s target price would suggest a potential upside of 22.06% from the stock’s previous close.

Several other research firms also recently weighed in on ALNY. Cowen and Company reiterated a “buy” rating and set a $100.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, July 11th. Vetr downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 target price for the company. in a research note on Monday, May 15th. Jefferies Group LLC set a $102.00 target price on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 25th. Piper Jaffray Companies set a $118.00 target price on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 15th. Finally, Credit Suisse Group raised their target price on Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 27th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $84.93.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) traded down 15.42% during midday trading on Thursday, hitting $72.76. 5,033,657 shares of the stock were exchanged. The stock’s 50-day moving average price is $82.34 and its 200-day moving average price is $67.32. Alnylam Pharmaceuticals has a 1-year low of $31.38 and a 1-year high of $89.45. The firm’s market capitalization is $6.67 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.22) by $0.12. The firm had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The firm’s revenue was up 82.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.05) EPS. On average, analysts forecast that Alnylam Pharmaceuticals will post ($5.18) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/09/07/alnylam-pharmaceuticals-inc-alny-receives-new-coverage-from-analysts-at-barclays-plc.html.

Several institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC boosted its position in shares of Alnylam Pharmaceuticals by 6.3% during the 2nd quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after acquiring an additional 815,270 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Alnylam Pharmaceuticals by 0.3% during the 1st quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock valued at $617,111,000 after acquiring an additional 31,208 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 13.4% during the 2nd quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after acquiring an additional 759,295 shares during the last quarter. BlackRock Inc. boosted its position in shares of Alnylam Pharmaceuticals by 9.3% during the 2nd quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock valued at $413,811,000 after acquiring an additional 441,957 shares during the last quarter. Finally, Baillie Gifford & Co. boosted its position in shares of Alnylam Pharmaceuticals by 2.9% during the 2nd quarter. Baillie Gifford & Co. now owns 3,431,316 shares of the biopharmaceutical company’s stock valued at $273,681,000 after acquiring an additional 96,805 shares during the last quarter. Hedge funds and other institutional investors own 94.27% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.